CD274 and neoplasm: Such a combinational therapy showed an obviously improved efficacy in eliminating primary tumors, and the further synergism with the immune checkpoint blockade therapy mediated by the anti-PD-L1 antibody could significantly inhibit the distant tumors in 4T1 tumor-bearing-mouse models (Figure 5b–d).